PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 5, 2026SLAS TECHNOLOGY0 citationsOpen Access

Empowering chemists in drug design: Delivering AI solutions through an ELN framework at the enterprise level

View Full Paper
TQTing QinACAparna ChandrasekaranJHJack Hoffman

Key Points

  • To improve the adoption of AI in drug discovery by providing a user-friendly framework using Electronic Lab Notebooks.
  • Developed an ELN-based framework that formalizes AI workflows as ELN protocols
  • Integrated AI execution as ELN experiments
  • Adhered to FAIR principles for enhanced data management
  • The framework effectively enhances user-friendliness for chemists
  • Promotes real-time compound design considering synthetic feasibility
  • Empowers chemists to contribute actively to the drug design process

Abstract

Artificial intelligence (AI) holds immense potential to revolutionize drug discovery, yet its widespread adoption within scientific enterprises faces significant hurdles. Key challenges include ensuring user-friendliness, managing complex workflows, and integrating diverse datasets. To address these issues, we propose a novel framework that leverages the familiar Electronic Lab Notebook (ELN) paradigm. By formalizing AI workflows as ELN protocols and treating AI execution as ELN experiments, the proposed system provides a scalable, traceable, and user-oriented deployment strategy that aligns with existing laboratory practices. This ELN-based framework adheres to FAIR principles, enhancing data findability, accessibility, interoperability, and reusability. By mirroring the intuitive ELN interface, our solution empowers bench chemists to easily access and utilize cutting-edge AI tools, enabling them to move beyond purely synthetic roles and fully engage as medicinal chemists. This allows chemists to design compounds with real-time consideration of synthetic feasibility and to actively contribute to the drug design process with their practical expertise, thereby accelerating drug discovery efforts and maximizing the return on AI investments.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Qin et al. (2026) studied this question.

synapsesocial.com/papers/69843360f1d9ada3c1fb073dhttps://doi.org/10.1016/j.slast.2026.100392
Ask AI
Helpful
Bookmark
Share
View Full Paper